SOD1 and gastric neoplasm: Moreover, JS‐K administration (1.5 and 3 mg/kg) significantly decreased SOD1 and catalase activity in gastric tumour tissues (Figure 6G); therefore, JS‐K could decrease SOD1 and catalase activity in vivo and in vitro, which would also contribute to JS‐K‐induced ROS accumulation.